CRISPR Therapeutics (CRSP) PT Lowered to $52 at Stifel Following Q1 Report, "Continue to be Positive on CTX001 but Skepticism Towards CAR-T Programs"
Tweet Send to a Friend
Stifel analyst Benjamin Burnett lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $52.00 (from $64.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
